Zobrazeno 1 - 10
of 17
pro vyhledávání: '"63"'
Autor:
L Prior, M Teo, M Greally, C Ward, C O'Leary, R Aslam, W Darwish, N Ahmed, G Watson, D Kelly, L Kiely, A Hassan, J Gleeson, H Featherstone, M Lim, H Murray, D Gallagher, J Westrup, B Hennessy, G Leonard, L Grogan, O Breathnach, A Horgan, L Coate, D O'Mahony, S O'Reilly, R Gupta, M Keane, K Duffy, M O'Connor, J Kennedy, J McCaffrey, M Higgins, C Kelly, D Carney, G Gullo, J Crown, J Walshe
Publikováno v:
Cancer Research. 78:P6-08
Background Pregnancy associated breast cancer (PABC) is defined as breast cancer (BC) diagnosed during the gestational period (GP) or in the first year postpartum (PP). Despite its infrequent occurrence, the incidence of PABC appears to be rising due
Autor:
Keiko Kajitani, Yoshie Kobayashi, Akiko Emi, N Gouda, Takayuki Kadoya, Morihito Okada, Norio Masumoto, Hideo Shigematsu
Publikováno v:
Cancer Research. 76:P4-09
Background: Wnt5a is a representative ligand that activates the β-catenin-independent pathways. The purpose of our study is to elucidate the implication of Wnt5a expression in breast cancer. Materials and methods: One hundred seventy eight breast ca
Autor:
Vassiliki Karantza, Seok Jin Nam, Ji-Yeon Kim, Seok Won Kim, Shawna R Calhoun, Mark Marsico, Yeon Hee Park, Jong Han Yu, Sohee Lee, Seri Park, Gursel Aktan, Jeong Eon Lee
Publikováno v:
Cancer Research. 80:P2-09
Background: Estrogen receptor (ER) expression is a predictive and prognostic factor in breast cancer. While the clinical benefit of endocrine therapy is indisputable, evidence suggests patients with low-ER expression (immunohistochemistry (IHC) 1-10%
Autor:
E. Shelley Hwang, Abigail S. Caudle, Rebecca A. Shelby, Michelle J. Naughton, Amylou C. Dueck, Briant Fruth, Gretchen Kimmick
Publikováno v:
Cancer Research. 80:P5-14
Background: Side effects of and adherence to aromatase inhibitors in women with ductal carcinoma in situ are not well described. Methods: Postmenopausal women in a prospective phase II study of neoadjuvant letrozole for estrogen receptor positive DCI
Autor:
Miguel Martin, J. Thaddeus Beck, Lacey M. Litchfield, Joohyuk Sohn, Hillary T. Graham, Matthew P. Goetz, Seock-Ah Im, Angelo Di Leo, Sameera R. Wijayawardana, Masakazu Toi, Antonio Llombart-Cussac, Hong Wang, Stephen R. D. Johnston, Valerie M. Jansen, Sara A. Hurvitz, Mario Campone
Publikováno v:
Cancer Research. 80:PD2-06
Background: Combination treatments of CDK4 & 6 inhibitors (CDK4 & 6i) with endocrine therapy (ET) have improved outcomes in patients with HR-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Aside from estrogen receptor positivity (
Autor:
Rohit Bhargava, S Smalley, A Onisko, David J. Dabbs, K Serdy, Adam Brufsky, Beth Z. Clark, S Perkins
Publikováno v:
Cancer Research. 78:P4-08
Introduction The majority of publications regarding breast cancer GEPTs rarely supply detailed breast tumor histopathology in their outcome studies. As a result, the cost effective role of clinical risk assessment with histopathology of breast carcin
Autor:
Linda A. deGraffenried, K Lathrup, Aleksandra Gruslova, Virginia G. Kaklamani, K Kist, Andrew Brenner, Muralidhar Beeram, D Quach, David Cavazos, RJ Ramirez, L Lengfelder
Publikováno v:
Cancer Research. 77:P1-09
Introduction: Obesity is associated with poor breast cancer outcomes in postmenopausal women. Our prior retrospective studies have shown that use of nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with reduced recurrence in obese breast
Autor:
Ken-ichi Watanabe, Mari S. Oba, Shigehira Saji, Takashi Takeshita, Nobutaka Iwakuma, Norikazu Masuda, Yuichiro Kikawa, Naoki Niikura, Shinji Ohno, Takayuki Iwamoto, Kokoro Kobayashi
Publikováno v:
Cancer Research. 80:OT2-02
Background: Fulvestrant is one of the standard treatments for first- and second-line endocrine therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC). Palbociclib inhibits cyclin dependent kinase (CDK) 4 and CDK6 in vitro, resultin
Autor:
Ioannis Efstratiou, George Fountzilas, Sofia Chrisafi, Anna Batistatou, Olympia Tzaida, Eleni Timotheadou, Petroula Arapantoni-Dadioti, Flora Zagouri, Triantafyllia Koletsa, Sotiris Lakis, Dimitrios Pectasides, Georgia Gourgioti, Eleftheria Tsolaki, Alexandra Papoudou-Bai, Mattheos Bobos, Helen Gogas, Elena Fountzilas
Publikováno v:
Cancer Research. 75:P3-09
Background-Aim: The aim of the present study was to explore the efficacy of dose-dense sequential adjuvant chemotherapy followed by trastuzumab in HER2-positive patients according to the immunohistochemically (IHC) defined subtypes. Patients and meth
Publikováno v:
Cancer Research. 71:P5-13
Background: The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) recently recommended that estrogen receptor (ER) and progesterone receptor (PR) values be considered positive in the evaluation of breast canc